SCHEMBL264552

SCHEMBL264552

OC1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.52
NT5E P21589 1/20 0.51
TACR2 P21452 3/20 0.48
GJB2 P29033 1/20 0.47
SSTR1 P30872 1/20 0.47
SSTR2 P30874 1/20 0.47
SSTR4 P31391 1/20 0.47
SSTR3 P32745 1/20 0.47
SSTR5 P35346 1/20 0.47
PTPN1 P18031 7/20 0.46
CDC25B P30305 6/20 0.46
PTPN2 P17706 3/20 0.46
PTPN11 Q06124 3/20 0.46
PTPN6 P29350 2/20 0.46
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
PDE4D Q08499 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2562480 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL14747295 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL1562064 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL19745164 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL16727960 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL12896357 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL1561335 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL5027926 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL1562065 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1
SCHEMBL20223437 1.00 HTR1A (0.52) HTR1ANT5ETACR2GJB2SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278436-B2 Glycosylated warfarin analogs and uses thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-10-02 US claimed
US-20100267655-A1 Glycosylated Warfarin Analogs and Uses Thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-10-21 US claimed
WO-2010014814-A2 GLYCOSYLATED WARFARIN ANALOGS AND USES THEREOF WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-02-04 WO claimed
US-20260042867-A1 ANTIBODY REPURPOSING SRI INTERNATIONAL (US) 2026-02-12 US disclosed
EP-4591935-A2 METHODS FOR THE PREPARATION OF RIBOSIDES Gilead Sciences, Inc. (US) 2025-07-30 EP disclosed
EP-4588928-A2 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS Gilead Sciences, Inc. (US) 2025-07-23 EP disclosed
CN-113549120-B Method for preparing ribonucleoside 吉利德科学公司 2025-04-29 CN disclosed
CN-108348526-B Methods of treating arenaviridae and coronaviridae viral infections 吉利德科学公司 2025-04-25 CN disclosed
EP-4036099-B1 METHODS FOR THE PREPARATION OF RIBOSIDES GILEAD SCIENCES INC (US) 2025-03-19 EP disclosed
US-20240409575-A1 METHODS OF PREPARING 1'-CYANO NUCLEOSIDES GILEAD SCIENCES, INC. 2024-12-12 US disclosed
CN-118994170-A Process for preparing 1' -cyanonucleosides 吉利德科学公司 2024-11-22 CN disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
EP-1970445-A1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS Riken (JP) 2008-09-17 EP disclosed
US-20080171787-A1 COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-07-17 US disclosed
US-20070185063-A1 Seven-membered ring nucleosides IDENIX PHARMACEUTICALS, INC. 2007-08-09 US disclosed
EP-1397376-B1 METHOD FOR PRODUCING PERBENZYLATED 1-O-GLYCOSIDES SCHERING AG (DE) 2005-05-04 EP disclosed
EP-1261614-B1 METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES SCHERING AG (DE) 2004-01-07 EP disclosed
US-6545135-B2 Alkylation SCHERING AKTIENGESELLSCHAFT (DE) 2003-04-08 US disclosed
US-20020002274-A1 Process for the production of perbenzylated 1-0-glycosides SCHERING AKTIENGESELLSCHAFT 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171787-A1 COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE TUBB6, TUBB, TUBA1C HTR1A 4715/4885NT5E 788/4885TACR2 2051/4885
US-20240409575-A1 METHODS OF PREPARING 1'-CYANO NUCLEOSIDES PNP, TYMP, DUT HTR1A 1323/4885NT5E 69/4885TACR2 2790/4885
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS HTR1A 4285/4885NT5E 170/4885TACR2 4788/4885
US-20260042867-A1 ANTIBODY REPURPOSING CD47, SSB, IGSF11 HTR1A 584/4885NT5E 1154/4885TACR2 3277/4885
US-20100267655-A1 Glycosylated Warfarin Analogs and Uses Thereof GPI, UGGT1, GALE HTR1A 4865/4885NT5E 422/4885TACR2 2803/4885
US-20070185063-A1 Seven-membered ring nucleosides NSUN2, NSUN3, HAVCR2 HTR1A 3963/4885NT5E 158/4885TACR2 4573/4885
US-20020002274-A1 Process for the production of perbenzylated 1-0-glycosides STT3B, MAN1B1, OSTC HTR1A 3493/4885NT5E 4064/4885TACR2 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.